In Conversation with Matt Dolan

As a senior research analyst focused on medical technology: (devices and diagnostics) with ROTH Capital Partners, Matt Dolan’s investment views have been cited by a “Who’s Who” of publications on Wall Street. Prior to joining Roth in 2003, Mr. Dolan, a graduate of Northwestern University, formed a trading group at the Chicago Board of Trade [...]

TearLab Osmolarity System gets CLIA Waiver from FDA

The FDA has granted a waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity System. The FDA took the action after reviewing and accepting labeling submitted to it by TearLab. “We believe that, with CLIA Waiver and Medicare reimbursement in place, and with the updated American Academy [...]

TearLab taps social media for dry eye awareness

During the past six months, TearLab (NASDAQ:TEAR;TSX:TLB) has initiated a series of social media campaigns as part of an innovative strategy to increase the awareness of dry eye disease (DED) with both patients and doctors. The program is also designed to demonstrate how its diagnostic test for dry eye can change the paradigm of dry [...]

Roth starts TearLab at buy

Roth Capital Partners has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with the “buy” rating and 12-month price target of $2.20. The stock was quoted at $1.42, up 12%, Thursday morning. Analyst Matt Dolan writes that he expects company’s sales to “ramp steadily over the next several quarters, with the potential for a more substantial acceleration [...]

Data released on impact of tear osmolarity on Lasik outcomes

Data has been presented at the European Society of Cataract and Refractive Surgeons Annual Congress in Vienna from a multi-site refractive surgery center study designed to determine how pre- and post-Lasik tear osmolarity levels relate to rates of Dry Eye Disease (DED) and DED symptoms. TearLab (NASDAQ:TEAR; TSX:TLB) osmolarity testing, OSDI symptomology, as well as [...]

TearLab launches consumer website for dry eye disease

TearLab (NASDAQ:TEAR; TSX:TLB) has launched “allaboutdryeye.com,” a new consumer website and social media program focused on supporting the company’s Accredited Dry Eye Centers program in North America. Allaboutdryeye.com was designed to help people suffering from dry eye disease (DED) by providing a place for them to share their experiences and ask questions, discover the science [...]

AOA newsletter focuses on DED

OSMOLARITY AND TEARLAB SEEN AS SINGLE BEST TEST FOR DED DIAGNOSIS The August issue of the American Optometric Association’s CLCS newsletter is devoted to ocular surface and dry eye disease, reflecting how the optometric community is now starting to embrace dry eye disease. Contact Lens and Cornea Section chairman LaMar Zigler, pointing to the value [...]

TearLab gets IGel reimbursement in Germany

TearLab (NASDAQ:TEAR; TSX:TLB) has received a unique, new “individual health benefits” or IGel code that applies to its osmolarity test for dry eye disease in Germany, effective immediately. IGel is the self-pay coding system that enables reimbursement for insured individuals. The system runs parallel to the state funding system and allows practitioners greater flexibility in [...]

TearLab U.S. patent expands testing beyond osmolarity

TearLab (NASDAQ:TEAR; TSX:TLB) has been granted a U.S. patent, entitled “Biomarker Normalization,” which gives the company broad and blocking intellectual property regarding the ability to compensate for first order dynamics in the eye, which is fundamental to accurate tear biomarker analysis, whether involving proteins, genes, or small molecules. The patent allows TearLab to build on [...]

TearLab gets osmolarity CPT code from AMA

The American Medical Association has published a new Current Procedural Terminology code that will apply to TearLab’s (NASDAQ:TEAR; TSX:TLB) osmolarity test for dry eye disease, effective Jan. 1, 2011. CPT codes are the most widely accepted form of medical nomenclature used to report medical procedures and services under public and private health insurance programs in [...]

Next Page »